TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of TAK-085 in Participants With Hypertriglyceridemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants with values of fasting triglyceride level at Visit 2 (Week -4) and Visit 3 (Week -2) are 150 mg/dL or higher and less than 750 mg/dL, and the difference between these 2 values is within 30% of the higher one.~2. Participants with differences between 2 values of fasting Low density lipoprotein - cholesterol level measured at Visit 2 (Week -4) and Visit 3 (Week -2) are within 25% of the higher one.~Exclusion Criteria:~1. Participants who have coronary artery diseases (eg, confirmed myocardial infarction and angina pectoris) within 6 months prior to Visit 1 (Week -8) or participants with a history of revascularization.~2. Participants who received aortic aneurysmectomy or is complicated with aortic aneurysm within 6 months prior to Visit 1 (Week -8).~3. Participants who have a history or complication of a clinically significant hemorrhagic disease (eg, hemophilia, capillary fragility illness, digestive tract ulcer, urinary tract hemorrhage, hemoptysis, vitreous haemorrhage and so forth) within 6 months prior to Visit 1 (Week -8).~4. Participants who have been diagnosed with pancreatitis.~5. Participants who have been diagnosed with lipoprotein lipase (LPL) deficiency, apolipoprotein C-II deficiency or type III familial hyperlipidemia.~6. Participants with complication of Cushing's syndrome, uremia, systemic lupus erythematosus (SLE) or serum dysproteinemia.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- TAK-085 2 g (Type: EXPERIMENTAL): TAK-085 2 g, orally, once daily for up to 12 weeks.
- TAK-085 4 g (Type: EXPERIMENTAL): TAK-085 2 g, orally, twice daily for up to 12 weeks.
- EPA-E 1.8 g (Type: EXPERIMENTAL): Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with type 1 diabetes mellitus: Fasting c-peptide \< 0.1nmol/l on insulin therapy for more than 12 months with or without history of diabetic ketoacidosis and treatment with liraglutide at maximal tolerated doses for at least 6 months prior to start of the study.~* Willing to use a continuous glucose monitoring device (CGM) and regularly measuring their blood sugars four times daily~* HbA1c of less than or equal to 11%.~* Well versed with carbohydrate counting~* Age 18-75 years~Exclusion Criteria:~* Type 1 diabetes for less than 12 months.~* Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous four weeks~* Hepatic disease (transaminase \> 3 times normal) or cirrhosis~* ESRD on hemodialysis; and or e-GFR less than 30 ml/min/1.73m2~* HIV or Hepatitis C positive status~* Participation in any other concurrent clinical trial~* Any other life-threatening, non-cardiac disease~* Use of an investigational agent or therapeutic regimen within 30 days of study~* History of pancreatitis~* Pregnancy~* Inability to give informed consent~* History of gastroparesis~* History of medullary thyroid carcinoma or MEN 2 syndrome~* Family history of MEN 2, Family history of medullary thyroid cancer, or familial medullary thyroid cancer~* Women of childbearing potential who are not using adequate contraception~* Women who are pregnant~* History of serious hypersensitivity reaction to these agents.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 12 weeks of treatment with Insulin, Liraglutide and Dapagliflozin Placebo
- Active drugs (Type: ACTIVE_COMPARATOR): 12 weeks of treatment with Insulin, Liraglutide and Active Dapagliflozin Drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult Women (≥ 18 years old).~* Histologically or cytologically confirmed invasive breast carcinoma with local recurrence or radiological evidence of metastatic disease.~* Must have at least one lesion that can be accurately measured or bone lesions in the absence of measurable disease.~* HER2+ patients by local laboratory testing (IHC 3+ staining or in situ hybridization positive).~* Prior trastuzumab and/or chemotherapy (taxanes included) as neo-adjuvant or adjuvant treatment is allowed but should be discontinued \> 12 months prior to randomization.~* Prior treatment for breast cancer with endocrine therapy (adjuvant or metastatic settings) is allowed but should be discontinued at randomization. Patients treated with bisphosphonates at entry or who start bisphosphonates during study may continue this therapy during protocol treatment.~* Documentation of negative pregnancy test.~* Organ functions at time of inclusion.~Exclusion Criteria:~* Prior mTOR inhibitors for the treatment of cancer.~* Other anticancer therapy for locally advanced or metastatic breast cancer except for prior hormonal therapy.~* Patients with only non-measurable lesions other than bone metastasis (e.g. pleural effusion, ascites, etc).~* Radiotherapy to ≥ 25% of the bone marrow within 4 weeks prior to randomization~* History of central nervous system metastasis.~* Impairment of gastrointestinal (GI) function or GI disease or active ulceration of the upper gastrointestinal tract.~* Serious peripheral neuropathy.~* Cardiac disease or dysfunction.~* Uncontrolled hypertension.~* HIV.~* Pregnant,

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Everolimus + Paclitaxel + Trastuzumab (Type: EXPERIMENTAL): Everolimus 10 mg daily in combination with paclitaxel 80mg/m2 weekly on days 1, 8, 15 and trastuzumab 2mg/kg weekly on days 1, 8, 15, 22
- Placebo + Paclitaxel + Trastuzumab (Type: PLACEBO_COMPARATOR): Placebo of everolimus 10 mg daily in combination with paclitaxel 80mg/m2 weekly on days 1, 8, 15 and trastuzumab 2mg/kg weekly on days 1, 8, 15, 22

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigating the Efficacy and Safety ICATIBANT For The Treatment of Patients With SARS-CoV-2 (COVID-19) Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. adult patients (18 years or older), both sexes~2. Sars-CoV-2 infection confirmed by PCR less than 4 days before randomization~3. hospitalized with a diagnosis of SARS-CoV-2 pneumonia~4. radiographic evidence of pulmonary infiltrates~5. grade 4 or 5 on the ordinal scale for the evaluation of the patient's clinical condition~6. pO2/FiO2 \<380~7. men and women of childbearing age who have heterosexual relations must be agreement to use the safe method(s) of contraception~8. obtaining the informed consent of the patient or the legal representative.~Exclusion Criteria:~1. imminent death (life expectancy less than 72h)~2. known hypersensitivity or known adverse reactions to the study drug, or its metabolites or excipients of the formulation~3. invasive mechanical ventilation~4. participation in any other clinical trial~5. ALT or AST \> 5 x ULN~6. creatinine clearance \<50 mL/min using the Cockcroft-Gault formula for participants '18 years old \[Cockcroft 1976\]~7. patients with recent acute coronary syndrome (\<1 month)~8. patients with a history of stroke~9. positive pregnancy test~10. pregnant or lactating woman

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care (SoC) (Type: ACTIVE_COMPARATOR): None
- SoC + Icatibant (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 PK, Bioavailability, Safety Study of Clonidine MBT w Catapres in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Main Inclusion Criteria:~* Healthy males or females (non-pregnant/non-lactating) aged 18 - 50 years.~* A Body Mass Index (BMI) of 18-30.~* No clinically significant abnormal serum biochemistry, haematology and urine examination values.~* A negative urinary drugs of abuse screen.~* Negative HIV and Hepatitis B and C results.~* No clinically significant abnormalities in 12-lead electrocardiogram (ECG).~* No clinically significant abnormalities in blood pressure or pulse.~* No allergy or sensitivity to clonidine or any of its excipients.~* No allergy to milk or milk derivatives.~* Subjects must provide written informed consent to participate in the study~Main Exclusion Criteria:~* Current or past medical condition that might significantly affect the pharmacokinetic or~* pharmacodynamic response to clonidine.~* Participation in a New Chemical Entity clinical study within the previous 3 months or a marketed drug clinical study within the previous 30 days.~* Pathological condition of the oral cavity that would affect administration via the buccal route.~* Raynaud's disease or other peripheral vascular disease.~* Receipt of regular medication within 14 days of the first dose that may have an impact on the safety and objectives of the study (at the Investigator's discretion).~* Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or metabolic dysfunction.~* Symptomatic postural hypotension evident on screening~* History or evidence of Suicidal Ideation and/or behaviour as determined by using Columbia-Suicide Severity Rating Scale (C-SSRS)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Clonidine MBT 50µg (Type: EXPERIMENTAL): Each subject will receive the following treatments in random order over 3 Treatment Periods (1 treatment/period): Clonidine MBT 50µg single dose, Clonidine MBT 100μg single dose ,a single-dose of reference catapres 100μg tablets.
- Clonidine MBT 100µg (Type: EXPERIMENTAL): Each subject will receive the following treatments in random order over 3 Treatment Periods (1 treatment/period): Clonidine MBT 50μg single dose, Clonidine MBT 100µg single dose ,a single-dose of reference catapres 100μg tablets..
- Catapres 100μg (Type: ACTIVE_COMPARATOR): Each subject will receive the following treatments in random order over 3 Treatment Periods (1 treatment/period): Clonidine MBT 50μg single dose, Clonidine MBT 100μg single dose ,a single-dose of reference catapres 100μg tablets.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must have symptomatic AF~* Subject must have adequate anticoagulant therapy~Exclusion Criteria:~* Subject may not have Class IV congestive heart failure.~* Subject may not have uncorrected electrolyte imbalance.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age~* relapsed CD20+ indolent B-cell non-Hodgkin's lymphoma~* documented history of response of \>/= 6 months duration from last rituximab-containing regimen~* clinical indication for treatment as determined by the investigator~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~Exclusion Criteria:~* prior use of any investigational monoclonal antibody within 6 months of study start~* prior use of any anti-cancer vaccine~* prior use of rituximab within 8 weeks of study entry~* radioimmunotherapy within 3 months prior to study entry~* Central Nervous System (CNS) lymphoma or evidence of transformation to high-grade or diffuse large B-cell lymphoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Obinutuzumab (Type: EXPERIMENTAL): Participants received 1000 mg obinutuzumab intravenous (IV) infusion once a week on Days 1, 8, 15, and 22 in the Induction Period. 2 months following the last infusion, participants without disease progression, were eligible to receive a 1000 mg IV infusion every two months for 2 years in the Extension Period. All participants received oral acetaminophen/ paracetamol (1000 mg) and an antihistamine such as diphenhydramine (50-100 mg), 30-60 minutes prior to each infusion.
- Rituximab (Type: ACTIVE_COMPARATOR): Participants received 375 mg/m\^2 rituximab IV infusion once a week on Days 1, 8, 15 and 22 in the Induction Period. 2 months following the last infusion, participants without disease progression were eligible to receive a 375 mg/m\^2 rituximab IV infusion once every two months for 2 years in the Extension Period. All participants received oral acetaminophen/ paracetamol (1000 mg) and an antihistamine such as diphenhydramine (50-100 mg), 30-60 minutes prior to each infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DVD Lifestyle Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Recent VA primary care measured BMI between 30.0-44.9 kg/m2 (at facility in pacific or mountain time zone)~* Access to DVD player or internet~* Able to participate fully in all study protocol/procedures including informed consent~Exclusion Criteria:~* Inability to speak, read, or understand English~* Recent weight loss interventions including use of prescription weight-loss medications, participation in group or individual weight loss programs provided by trained personnel, bariatric surgery (or plans for during the study period)~* Expected weight loss because of alternate explanations such as from illness~* High variability in weight due to fluctuations in volume status (ascites - liver disease, chronic heart failure)~* Safety and/or adherence concerns due to severe physical or mental health issues, or life expectancy \<24 months~* Pregnant, lactating, or planning to become pregnant during the study period;~* Participation in other intervention studies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- behavioral lifestyle intervention (Type: EXPERIMENTAL): The investigators will provide participants with the the behavioral lifestyle intervention
- usual care control (Type: NO_INTERVENTION): participant in this arm will continue with usual care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Olanzapine for Nausea After Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults age ≥ 18 and ≤ 50 years old~* Patient scheduled to undergo ambulatory surgery under general anesthesia~* Willing and able to provide informed consent~Exclusion Criteria:~* Unable to swallow pills~* Current use of typical or atypical anti-psychotic medications~* History of allergy to olanzapine~* Pregnancy/Lactation (subjects of child-bearing potential will have a urine pregnancy test performed the day of surgery)~* History of QTc \> 450ms or torsades de pointes~* Current use of antihypertensive medication~* Diabetes Mellitus~* Clinically significant cardiovascular disease defined as follows:~  1. Myocardial infarction or unstable angina within 6 months prior to the day of planned surgery.~ 2. History of serious ventricular arrhythmia (i.e.: ventricular tachycardia or ventricular fibrillation) or cardiac arrhythmias requiring anti-arrhythmic medications, except for atrial fibrillation that is well controlled on anti-arrhythmic medication.~ 3. New York Heart Association (NYHA) Class II or higher congestive heart failure.~* Postural hypotension or vasovagal syncope within 6 months of planned surgery.~* Hypotension on day of surgery, defined as a systolic blood pressure \< 90mm Hg or a diastolic pressure \< 60mm Hg.~* Seizure disorder~* Clinically active prolactinoma~* Hepatic disease~* Poorly controlled diabetes~* Pre-operative blood glucose \> 250 mg/dL~* Narrow angle glaucoma~* Parkinson's disease~* Lewy body dementia

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Olanzapine (Type: EXPERIMENTAL): 10mg pill
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females between 18 and 45 years of age.~2. History of grass and/or ragweed allergic rhinitis.~3. Positive skin test to grass and/or ragweed antigen.~4. Positive response to screening nasal challenge.~Exclusion Criteria:~1. Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.~2. Pregnant or lactating women.~3. Upper respiratory infection within 14 days of study start.~4. forced expiratory volume at one second (FEV1) \<80% of predicted at screening for subjects with history of mild asthma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- FF/PL, PL/OLO, FF/OLO, PL/PL (Type: OTHER): Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:~* fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL)~* PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO),~* FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO), and~* placebo (PL) nasal spray and PL eye drops (PL/PL).
- PL/OLO, FF/OLO, PL/PL, FF/PL (Type: OTHER): Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:~* PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO),~* FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO),~* placebo (PL) nasal spray and PL eye drops (PL/PL), and~* fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL).
- FF/OLO, PL/PL, FF/PL, PL/OLO (Type: OTHER): Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:~* FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO),~* placebo (PL) nasal spray and PL eye drops (PL/PL),~* fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL), and~* PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO).
- PL/PL, FF/PL, PL/OLO, FF/OLO (Type: OTHER): Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:~* placebo (PL) nasal spray and PL eye drops (PL/PL),~* fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL),~* PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO), and~* FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete